Abstract: An amorphous solid dispersions comprising an active pharmaceutical ingredient and pharmaceutical compositions comprising the amorphous solid dispersions. Also described herein are methods for preparing and using such compositions. In some embodiments, an amorphous solid dispersion comprises an active pharmaceutical ingredient such as palbociclib or neratinib, one or more acids, and a high-molecular weight material.

Abstract: The present invention provides a selection method of array length of observation system, comprising: step S101: obtaining a seismic response equation for any point on ground based on wavefield propagation theory; step S102: determining at least one selection criterion of an optimum array length considering different factors according to the seismic response equation; step S103: obtaining the array lengths considering the different factors respectively according to the at least one selection criterion of the optimum array length; and step S104: integrating the array lengths considering the different factors and determining that the optimum array length is ?{square root over (2)} times the depth of the destination layer. Compared with conventional array length calculation method the demonstration method of array length as proposed in the present invention has the advantages of higher accuracy and applicability for destination layers.

Abstract: Provided are pharmaceutical compositions which include a mixture of a lipophilic active pharmaceutical ingredient such as nilotinib, a hydrophilic polymer, one or more surfactants, and optionally an adsorbent. Also described are methods for preparing and using such pharmaceutical compositions. In one aspect, disclosed herein is an amorphous solid dispersion comprising the active pharmaceutical ingredient.

Abstract: An apparatus comprising a first processor comprising first circuitry to track correctable errors detected by a first communication device of a second processor; and second circuitry to communicate with the second processor to initiate, based on the tracked correctable errors, a link recovery procedure for the first communication device.

Abstract: Provided are amorphous solid dispersions comprising an active pharmaceutical ingredient and pharmaceutical compositions comprising the amorphous solid dispersions. Also described herein are methods for preparing and using such compositions. In some embodiments, an amorphous solid dispersion comprises an active pharmaceutical ingredient such as palbociclib or neratinib, one or more acids, and a high-molecular weight material.

Abstract: Provided are amorphous solid dispersions comprising an active pharmaceutical ingredient and pharmaceutical compositions comprising the amorphous solid dispersions. Also described herein are methods for preparing and using such compositions. In some embodiments, an amorphous solid dispersion comprises an active pharmaceutical ingredient such as palbociclib or neratinib, one or more acids, and a high-molecular weight material.